Response to comment on 'Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity'

David J Goldhamer; John B Lees-Shepard

doi:10.7554/eLife.43928

Response to comment on 'Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity'

Elife. 2019 Jan 30:8:e43928. doi: 10.7554/eLife.43928.

Authors

David J Goldhamer¹, John B Lees-Shepard¹

Affiliation

¹ Department of Molecular and Cell Biology, University of Connecticut, Storrs, United States.

Abstract

We respond to concerns expressed by Pacifici and Shore (2019) about a recent paper (Lees-Shepard and Goldhamer, 2018a) in which we reported that the drug palovarotene can have severe side effects in a mouse model of fibrodysplasia ossificans progressiva.

Keywords: Fibrodysplasia ossificans progressiva; Palovarotene; RARγ agonist; growth plate; heterotopic ossification; human biology; medicine; mouse; regenerative medicine; skeletal toxicity; stem cells.

Publication types

Comment

MeSH terms

Animals
Mice
Myositis Ossificans*
Ossification, Heterotopic*
Pyrazoles
Stilbenes*

Substances

Pyrazoles
Stilbenes
Palovarotene